Sangamo is pioneering the future of genomic medicine
Sangamo Therapeutics is a genomic medicine company dedicated to translating groundbreaking science into medicines that transform the lives of patients and families afflicted with serious neurological disease. Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from diseases for which today’s medicine can only offer symptom management at best.
Minimum 15 minutes delayed. Source: LSEG
-
December 30, 2024
- Based on positive results from Phase 3 AFFINE trial, which met primary and secondary endpoints, Sangamo plans to explore all options to commercialize the asset, including seeking a potential new collaboration partner RICHMOND, Calif. --(BUSINESS WIRE)--Dec. 30, 2024-- Sangamo Therapeutics, Inc.
-
December 19, 2024
- Agreement grants Astellas rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - Sangamo to receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees and milestone
-
November 19, 2024
Sangamo plans to initiate enrollment of patients in the Phase 1/2 study for ST-503 in mid-2025 RICHMOND, Calif. --(BUSINESS WIRE)--Nov. 19, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the
-
November 12, 2024
Announced clear regulatory pathway to Accelerated Approval from U.S. Food and Drug Administration (FDA) for isaralgagene civaparvovec in Fabry disease, using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to
| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| SCHEDULE 13G/A | SCHEDULE 13G/A - Description |
View HTML | ||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA |
- More events are coming soon.
-
Nov 19 - Nov 21, 2024
-
Nov 12, 2024 at 4:30 PM EST